Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

This article has a correction. Please see:

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE - December 01, 2018

Biomarker studies

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Casey KA, Guo X, Smith MA, et al

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

Lupus Science & Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286